Posted by Michael Wonder on 30 Mar 2022
ViiV Healthcare announces US FDA approval of Cabenuva (cabotegravir, rilpivirine) for virologically suppressed adolescents living with HIV who are 12 years of age or older and weigh at least 35 kg
29 March 2022 - The expanded indication for the first and only complete long-acting HIV regimen provides an option with as few as six dosing days per year for virologically suppressed young people living with HIV.
ViiV Healthcare today announced that the US FDA has approved Cabenuva (cabotegravir, rilpivirine) for the treatment of HIV-1 in virologically suppressed adolescents (HIV-1 RNA less than 50 copies/mL) who are 12 years of age or older and weigh at least 35 kg on a stable antiretroviral regimen, with no history of treatment failure, and with no known or suspected resistance to either cabotegravir or rilpivirine.
